Joe Ross is vice president of LDR Spine’s US Marketing


LDR has announced that Joe Ross has joined the company as vice president of US marketing. In this new role, which strengthens the US organisation for LDR Spine, he will lead all aspects of commercial marketing and provide essential support for continued sales growth.

Christophe Lavigne, CEO,  said, “We are fortunate at LDR to be experiencing considerable revenue growth in the US market led by the success of our VerteBRIDGE line of lumbar and cervical zero-profile interbody fusion devices. It is critical that our organisational capabilities keep pace with our market presence, and Joe is uniquely qualified to lead our marketing efforts given his vast spine industry experience and knowledge. In addition, as we approach the upcoming review of the Mobi-C cervical artificial disc IDE clinical trial data by the FDA, Joe’s experience marketing PMA approved spine products will be of immense value.”

Ross brings to LDR more than fifteen years of spine device and biotech experience in sales, marketing, and business development. His most recent position was as vice president of Strategic Initiatives for Axial Biotech. Earlier, he spent more than eleven years at the DePuy Spine division of Johnson & Johnson in roles of increasing responsibility including worldwide vice president of New Business Development. He is a graduate of the University of Notre Dame and Troy University, and served five years as an officer in the United States Navy.

“I am thrilled to be joining LDR during this time of rapid growth and new product launches,” Ross said. “The VerteBRIDGE portfolio has been tremendously well received by the physician community, and we will be releasing two new applications of the technology in the first half of 2011. LDR is also particularly well positioned as one of only two companies to complete both a one and two level concurrent cervical artificial disc IDE trial with 2-year follow up, and Mobi-C may become a very important addition to the developing cervical arthroplasty market.”